Donkey-milk exosomes for oral octreotide

Oral peptide delivery has always had an ugly constraint hiding in plain sight: the intestine is designed to not let delicate proteins and peptides through.

For years, “oral peptides” mostly meant some mix of coatings, enzyme inhibitors, and permeability enhancers. That era is still very much alive, and it even produced real products. But once oral delivery becomes commercially plausible, the question shifts from can you get any of it across? to can you do it reliably, comfortably, and at scale?

A new paper in the International Journal of Pharmaceutics takes an unusually literal swing at “biomimetic” oral delivery: packaging octreotide inside exosomes isolated from donkey milk powder, with the goal of exploiting endogenous transport machinery rather than transiently pushing open epithelial junctions (PubMed).

The backdrop: oral octreotide already exists, but it comes with constraints

Octreotide is a somatostatin analogue used in chronic endocrine conditions like acromegaly. Clinically, it has largely lived in injection-first form factors, which can be effective but also create a steady burden for long-term patients.

In 2020, oral octreotide capsules using “transient permeation enhancer” technology received FDA approval for maintenance therapy in select patients with acromegaly. A 2024 clinical pharmacology review summarizes the basic trade: the approach can maintain biochemical control in trials, but it works by intentionally and transiently increasing gut permeability, which brings its own practical and formulation constraints (PubMed).

That context matters because it frames the question the new paper is really asking.

It is not “can octreotide be oral?” It is “can oral delivery be made to look more like normal biology?”

What the new study built: exosomes as a protective, transport-friendly carrier

Padakanti and colleagues isolated exosomes from donkey milk powder and then loaded octreotide using a pH-gradient method (PubMed). The exosomes they describe were on the order of ~140 nm in size and carried a set of markers and transport-associated proteins consistent with a vesicle that can fuse, traffic, and potentially move across epithelial barriers.

From a platform perspective, the key idea is simple:

Instead of making the intestinal wall more permeable for a moment, try to ride existing transcytosis and membrane-fusion pathways that already move cargo across cells.

Signals that matter (and what they don’t prove)

The paper reports several stepwise signals that, together, form a coherent proof-of-concept.

First, in an MDCK monolayer model, the exosome formulation produced a large relative increase in permeability versus free octreotide, which the authors frame as a “37-fold” enhancement.

Second, they used in silico pharmacokinetic modeling (GastroPlus) to project a large rise in fraction absorbed, and then they tested the formulation in mice.

In BALB/c mice, oral dosing of octreotide-loaded exosomes (2 mg/kg) produced a substantially higher systemic exposure than free octreotide, with the authors reporting a 16-fold AUC increase (AUC0–24 of 435,200 pg·h/mL for the exosome formulation) and biodistribution signals in multiple organs (PubMed).

Those are the kind of numbers that grab attention. But they are not a “solved” platform yet.

A mouse proof-of-concept does not answer the hard questions that determine whether an oral peptide technology becomes a product: lot-to-lot consistency, stability, food effects, chronic tolerability, and whether the biology that helped in vitro actually scales in vivo across species.

A useful contrast: some ‘carrier’ ideas help, but enhancers still dominate in simple models

If you zoom out, this exosome work sits in a crowded landscape of alternative carrier approaches for oral peptide delivery.

One fresh example, also focused on octreotide, used lipid-functionalized mesoporous silica (SYLOID) with stearic acid to increase apparent permeability in a Caco-2 model. The complex improved transport versus free octreotide, but the paper also highlights a pragmatic truth: conventional permeation enhancers (for example SNAC, and especially SNAC plus TPGS in that model) can move much larger amounts across the monolayer (PubMed).

That is not an argument against new carriers.

It is a reminder that “better than baseline” is not the only bar. If an enhancer-based formulation already works clinically, a new platform needs a compelling advantage: fewer constraints, better tolerability, better reproducibility, or a clearer path to scaling.

The real story is manufacturing, not just biology

Exosomes are appealing precisely because they are biological. They already come with proteins and lipids that can protect cargo and interact with cells.

But that same biology is what will make skeptics push hardest.

If the carrier is derived from a natural source (here, donkey milk powder), the commercialization story becomes a manufacturing story: how you standardize the source material, how you ensure purity and safety, how you prevent contaminants, and how you lock in consistent performance across lots.

Even before human trials, a platform like this has to earn trust by showing that “the same thing” is being made every time.

What would actually raise confidence next

If you treat this paper as a serious platform signal (not a hype headline), the next milestones are straightforward.

The most confidence-building step would be an independent replication plus a head-to-head comparison against approved oral octreotide capsules in an animal model.

After that, the platform needs to show what product teams care about:

a clear manufacturing spec (yield, purity, lot-to-lot consistency)
stability under realistic storage conditions
fed versus fasted performance
chronic dosing tolerability

If those boxes start to get checked, exosome-based oral delivery becomes more than a clever idea. It becomes an alternative answer to the same question oral octreotide already forced the field to confront: what are you willing to trade, and what constraints are you trying to escape?